Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas
Results from several randomised studies show a clinical benefit of a maintenance therapy
with rituximab in follicular lymphomas. The advantage of a maintenance therapy in other
indolent and mantle cell lymphomas is - due to the lower incidence of these diseases- not
well investigated.
This study tries to determine the significance of an extended maintenance therapy with
rituximab in follicular lymphomas and the significance of a maintenance therapy other
indolent and mantle cell lymphomas compared to observation.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
5 years and ongoing
Yes
Mathias Rummel, Dr
Principal Investigator
University of Giessen
Germany: Paul-Ehrlich-Institut
NHL 7-2008
NCT00877214
April 2009
April 2020
Name | Location |
---|